EverSource Wealth Advisors LLC lifted its position in shares of Verona Pharma plc (NASDAQ:VRNA – Free Report) by 3,074.2% during the fourth quarter, HoldingsChannel reports. The fund owned 6,158 shares of the company’s stock after acquiring an additional 5,964 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Verona Pharma were worth $286,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also recently added to or reduced their stakes in the company. Personal CFO Solutions LLC purchased a new stake in shares of Verona Pharma in the fourth quarter valued at approximately $284,000. Raymond James Financial Inc. acquired a new stake in Verona Pharma in the fourth quarter valued at $225,000. M&T Bank Corp purchased a new stake in shares of Verona Pharma during the 4th quarter worth $243,000. Keybank National Association OH acquired a new position in shares of Verona Pharma during the 4th quarter worth $300,000. Finally, Wrapmanager Inc. purchased a new position in shares of Verona Pharma in the 4th quarter valued at about $207,000. 85.88% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In related news, insider Kathleen A. Rickard sold 79,264 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $8.35, for a total transaction of $661,854.40. Following the transaction, the insider now directly owns 2,608,976 shares in the company, valued at approximately $21,784,949.60. This represents a 2.95 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.80% of the stock is owned by corporate insiders.
Verona Pharma Stock Performance
Analysts Set New Price Targets
A number of research firms recently commented on VRNA. Roth Capital set a $83.00 price objective on shares of Verona Pharma in a report on Friday, February 28th. Wells Fargo & Company upped their price target on Verona Pharma from $74.00 to $93.00 and gave the stock an “overweight” rating in a report on Friday, February 28th. Truist Financial reiterated a “buy” rating and set a $57.00 target price (up from $44.00) on shares of Verona Pharma in a research report on Wednesday, January 8th. Canaccord Genuity Group raised their price target on Verona Pharma from $44.00 to $72.00 and gave the company a “buy” rating in a research report on Wednesday, February 12th. Finally, Roth Mkm assumed coverage on shares of Verona Pharma in a research report on Friday, January 10th. They issued a “buy” rating and a $68.00 price objective on the stock. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $69.14.
View Our Latest Research Report on VRNA
Verona Pharma Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Featured Articles
- Five stocks we like better than Verona Pharma
- Stock Analyst Ratings and Canadian Analyst Ratings
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Upcoming IPO Stock Lockup Period, Explained
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How to Calculate Inflation Rate
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Want to see what other hedge funds are holding VRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Verona Pharma plc (NASDAQ:VRNA – Free Report).
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.